Neal Shore, MD of Carolina Urologic Research Center @UNCurology discusses the overall survival results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy for nonmetastatic castration-resistant prostate cancer presented at this year’s virtual ASCO.
Read here: https://meetinglibrary.asco.org/record/187482/abstract
Advertisement